Vigonvita Life Sciences Co., Ltd. (2630.HK) has launched its Hong Kong IPO. The subscription period runs from October 28 to November 3, with a global offering of 17,597,800 shares and a 15% over-allotment option. The offer price range is between HK$32.00 and HK$34.00 per share, with a minimum lot size of 200 shares and an entry fee of approximately HK$6,868.57. The shares are expected to list on the Hong Kong Stock Exchange on November 6. CITIC Securities is the sole sponsor for this offering.

Vigonvita: A Biopharmaceutical Innovator Focused on Neurological, Reproductive Health, and Viral Infections

Offer Ratio: 10% for Hong Kong public offering (1,759,800 shares), 90% for international placement (15,838,000 shares).

Offer Price: Between HK$32.00 and HK$34.00 per share; minimum 200 shares; entry fee approximately HK$6,868.57.

Subscription Period: October 28 to November 3 (pricing date is expected to be November 4).

Listing Date: November 6.

IPO Sponsor: CITIC Securities.

Company Overview

Founded in 2013, Vigonvita Life Sciences is a biopharmaceutical company focusing on small molecule drugs in the areas of neurological, reproductive health, and viral infections. The company has two core products: LV232 (anti-depressant) and TPN171 (treatment for erectile dysfunction). TPN171 has already been approved for sale in China and Uzbekistan. The company has established a diversified product pipeline covering the stages from pre-clinical to commercialization and has the capability for independent R&D, production, and commercialization.

Financial Information

According to the prospectus, Vigonvita's revenue for 2023, 2024, and the first four months of 2025 was approximately RMB 199.6 million, RMB 11.8 million, and RMB 13 million, respectively, with net profits of approximately RMB 6.4 million, and net losses of RMB 217.6 million and RMB 112.4 million, respectively. Based on the median offer price of HK$33.00, assuming no exercise of the over-allotment option, the company expects to raise a net amount of approximately HK$521.1 million. The funds will be used for core product R&D (around 38%), R&D for other candidate products (around 27%), construction of a Qingdao factory (around 10%), enhancing sales and marketing capabilities (around 15%), and working capital (around 10%).

uSMART launches “HK IPO Fee-Waiver Offer” – subscribe to new shares at zero cost

Margin subscription: 0 % interest, leverage up to 10×

Cash subscription: HK$0 handling fee

Grey-market trading supported

* 0 % interest applies to margin subscription amounts of HK$10 million or below.

^ All handling fees are waived for cash subscriptions.

This promotion is effective from 20 May 2025 until further notice. Certain high-profile IPOs may be excluded. The actual interest rates and fees charged are those shown in the uSMART App subscription interface; statutory government and exchange levies will still apply. The company reserves the right to amend, suspend or terminate the above offer or its terms and conditions at any time without prior notice, and its interpretation shall be final.

How to Subscribe for Vigonvita Life Sciences via uSMART HK

The uSMART HK App features an IPO Centre with exclusive perks, allowing clients to subscribe instantly to public offerings. After logging into the app, tap "Trade" at the bottom-right, go to "IPO Subscription," select Vigonvita Life Sciences, tap "Public Offer," enter your subscription quantity, and submit your order.

(Image source: uSMART HK App)